BioStem Technologies Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2023	FY 2022	FY 2021
Period Ending	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	-8.48	-7.19	-1.45
Depreciation & Amortization	0.23	0.22	0.28
Other Amortization	0.17	-	-
Loss (Gain) From Sale of Assets	-	-	-0.03
Stock-Based Compensation	6.67	5.38	1.19
Provision & Write-off of Bad Debts	-	0.15	-
Other Operating Activities	0.64	2.04	-0.62
Change in Accounts Receivable	-11.33	0.11	-0.29
Change in Inventory	-0.26	-0.14	0.21
Change in Accounts Payable	0.82	-0.08	-0.02
Change in Other Net Operating Assets	8.06	-0.2	0.61
Operating Cash Flow	-3.5	0.3	-0.11
Capital Expenditures	-0.11	-0.24	-0.04
Cash Acquisitions	-0.11	-0.23	-
Divestitures	-	-	0.04
Investing Cash Flow	-0.21	-0.47	-0.01
Long-Term Debt Issued	1.57	1.1	0.3
Total Debt Issued	1.57	1.1	0.3
Long-Term Debt Repaid	-0.77	-0.55	-0.06
Total Debt Repaid	-0.77	-0.55	-0.06
Net Debt Issued (Repaid)	0.8	0.55	0.23
Issuance of Common Stock	2.38	0.05	0.13
Financing Cash Flow	3.18	0.6	0.36
Net Cash Flow	-0.53	0.43	0.24
Free Cash Flow	-3.6	0.06	-0.15
Free Cash Flow Margin	-21.60%	0.87%	-3.51%
Free Cash Flow Per Share	-0.26	0.01	-0.01
Cash Interest Paid	0.48	0.23	0.33
Levered Free Cash Flow	-0.61	0.77	-
Unlevered Free Cash Flow	-0.34	1.07	-
Change in Working Capital	-2.72	-0.3	0.52

Source: S&P Global Market Intelligence. Standard template. Financial Sources.